Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1642, Issue 1-2, 2003, Pages 25-31

  Buechler, Christa ^a   Ullrich, Heidrun ^a   Aslanidis, Charalampos ^a   Bared, Salim Maa ^a   Lingenhel, Arno ^b   Ritter, Mirko ^a   Schmitz, Gerd ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Atherogenesis; Blood monocyte; Interleukin 6; Lipoprotein (a); Lysosomal acid lipase

Indexed keywords

ACID LIPASE; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TRIACYLGLYCEROL LIPASE;

ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; CYTOKINE RELEASE; DOWN REGULATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CULTURE; CORONARY ARTERY ATHEROSCLEROSIS; DNA MICROARRAY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LYSOSOME; METABOLISM; PREDICTION AND FORECASTING; SECRETION;

CELLS, CULTURED; CORONARY ARTERIOSCLEROSIS; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPIDEMIAS; INTERLEUKIN-6; LIPASE; LIPOPROTEIN(A); LYSOSOMES; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142120306     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(03)00083-1     Document Type: Article

References (31)

1. Kostner K.M., Kostner G.M. Lipoprotein(a): still an enigma? Curr. Opin. Lipidol. 13:2002;391-396.
2. Kronenberg F., Steinmetz A., Kostner G.M., Dieplinger H. Lipoprotein (a) in health and disease. Crit. Rev. Clin. Lab. Sci. 33:1996;495-543.
3. McLean J.W., Tomlinson J.E., Kuang W.J., Eaton D.L., Chen E.Y., Fless G.M., Scanu A.M., Lawn R.M. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 330:1987;132-137.
4. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J. Biol. Chem. 266:1991;2459-2465.
5. Allen S., Khan S., Tam S., Koschinsky M., Taylor P., Yacoub M. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J. 12:1998;1765-1776.
6. Klezovitch O., Edelstein C., Scanu A.M. Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein (a). Evidence for a critical involvement of elements in its C-terminal domain. J. Biol. Chem. 276:2001;46864-46869.
7. Stragliotto E., Camera M., Postiglione A., Sirtori M., Di Minno G., Tremoli E. Functionally abnormal monocytes in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 13:1993;944-950.
8. Giry C., Giroux L.M., Roy M., Davignon J., Minnich A. Characterization of inherited scavenger receptor over-expression and abnormal macrophage phenotype in a normolipidemic subject with planar xanthoma. J. Lipid Res. 37:1996;1422-1435.
9. Han K.H., Han K.O., Green S.R., Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocyte function. J. Lipid Res. 40:1999;1053-1063.
10. Garlichs C.D., John S., Schmeisser A., Eskafi S., Stumpf C., Karl M., Goppelt-Struebe M., Schmieder R., Daniel W.G. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation. 104:2001;2395-4000.
11. Rothe G., Gabriel H., Kovacs E., Klucken J., Stohr J., Kindermann W., Schmitz G. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 16:1996;1437-1447.
12. Buechler C., Ullrich H., Ritter M., Porsch-Oezcueruemez M., Lackner K.J., Barlage S., Friedrich S.O., Kostner G.M., Schmitz G. Lipoprotein (a) upregulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood. 97:2001;981-986.
13. Ullrich H., Lackner K., Schmitz G. Lipoprotein (a)-apheresis in the secondary prevention of coronary heart disease. Transfus. Sci. 94:1996;2150-2155.
14. Kraft H.G., Köchl S., Menzel H.J., Sandholzer C., Utermann G. The apolipoprotein (a) gene: a transcribed hypervariable region locus controlling plasma lipoprotein (a) concentration. Hum. Genet. 90:1992;220-230.
15. Kraft H.G., Lingenhel A., Köchl S., Hoppichler F., Kronenberg F., Abe A., Mühlberger V., Schönitzer D., Utermann G. Apolipoprotein (a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 16:1996;713-719.
16. Kostner G.M., Ibovnik A., Holzer H., Grillhofer H. Preparation of a stable fresh frozen primary lipoprotein(a) (Lp(a)) standard. J. Lipid Res. 40:1999;2255-2263.
17. Chirgwin J.M., Przybyla A.E., MacDonald R.J., Rutter W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:1979;5294-5299.
18. Schwartz B.S., Bradshaw J.D. Regulation of plasminogen activator inhibitor mRNA levels in lipopolysachcaride-stimulated human monocytes. J. Biol. Chem. 267:1992;7089-7094.
19. Ramharack D., Barkalow D., Spahr M.A. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler. Thromb. Vasc. Biol. 18:1998;984-990.
20. Baggio G., Donazzan S., Monti D., Mari D., Martini S., Gabelli C., Dalla V.M., Previato L., Guido M., Pigozzo S., Cortella I., Crepaldi G., Franceschi C. Lipoprotein (a) and lipoprotein profile in healthy centenarians. FASEB J. 12:1998;433-437.
21. Horvath L., Csaszar A., Falus A., Dieplinger H., Horvath A., Puskas E., Halm G., Banyai A., Paloczi K., Laszlo E., Kalabay L., Romics L., Fust G. IL-6 and lipoprotein(a) [LP(a)] concentrations are related only in patients with high apo(a) isoforms in monoclonal gammopathy. Cytokine. 18:2002;340-343.
22. Maor I., Aviram M. Oxidized low density lipoprotein leads to macrophage accumulation of unesterified cholesterol as a result of lysosomal trapping of the lipoprotein hydrolyzed cholesteryl ester. J. Lipid Res. 35:1994;803-819.
23. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull W. Jr., Rosenfeld M.E., Schaffer S.A., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. Arterioscler. Thromb. 14:1994;840-856.
24. Coates P.M., Langer T., Cortner J.A. Genetic variation of human mononuclear leukocyte lysosomal acid lipase activity. Relationship to atherosclerosis. Atherosclerosis. 62:1986;11-20.
25. Ries S., Buchler C., Schindler G., Aslanidis C., Ameis D., Gasche C., Jung N., Schambach A., Fehringer P., Vanier M.T., Belli D.C., Greten H., Schmitz G. Different missense mutations in histidine-108 of lysosomal acid lipase cause cholesteryl ester storage disease in unrelated compound heterozygous and hemizygous individuals. Human Mutat. 12:1998;44-51.
26. Schmitz G., Assmann G. Wolman disease and cholesteryl ester storage disease. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 6th ed. 1989;1623-1644 McGraw-Hill, New York.
27. Aslanidis C., Ries S., Fehringer P., Buechler C., Klima H., Schmitz G. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics. 33:1996;85-93.
28. Luc G., Bard J.M., Arveiler D., Ferrieres J., Evans A., Amouyel P., Fruchart J.C., Ducimetiere P. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME study. Atherosclerosis. 163:2002;377-384.
29. van Eck M., Bos I.S., Kaminski W.E., Orso E., Rothe G., Twisk J., Boettcher A., Van Amersfoort E.S., Christiansen-Weber T.A., Fung-Leung W.P., Van Berkel T.J., Schmitz G. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl. Acad. Sci. U. S. A. 99:2002;6298-6303.
30. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138:1999;419-420.
31. Testa R., Bonfigli A.R., Sirolla C., De Grazia G., Compagnucci P., Manfrini S., Fumelli D., Testa I. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in type 2 diabetic patients without complications. Diabetes Nutr. Metab. 13:2000;269-275.